Plus, news about CG Oncology, Opus Genetics and Valneva:
Surrozen’s pivot and capital raise: The South San Francisco drug developer is
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.